BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Buy" from Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have covered the stock in the last year is $13.83.

Separately, Needham & Company LLC restated a "buy" rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th.

BioCryst Pharmaceuticals Stock Down 0.7 %

Shares of BCRX traded down $0.03 during trading hours on Tuesday, reaching $4.38. 4,236,607 shares of the company traded hands, compared to its average volume of 3,305,727. The stock has a market capitalization of $902.94 million, a PE ratio of -3.71 and a beta of 1.90. BioCryst Pharmaceuticals has a fifty-two week low of $4.27 and a fifty-two week high of $9.06. The stock has a fifty day simple moving average of $5.18 and a 200 day simple moving average of $5.58.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analysts' expectations of $89.19 million. Research analysts predict that BioCryst Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of BCRX. Vanguard Group Inc. raised its position in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock valued at $106,405,000 after buying an additional 2,371,401 shares during the period. Avoro Capital Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 13.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company's stock worth $78,170,000 after acquiring an additional 1,500,000 shares in the last quarter. Braidwell LP lifted its stake in BioCryst Pharmaceuticals by 6.6% in the 4th quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company's stock worth $34,254,000 after acquiring an additional 355,497 shares in the last quarter. Kynam Capital Management LP lifted its stake in BioCryst Pharmaceuticals by 46.8% in the 4th quarter. Kynam Capital Management LP now owns 4,600,000 shares of the biotechnology company's stock worth $27,554,000 after acquiring an additional 1,466,807 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its stake in BioCryst Pharmaceuticals by 148.6% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock worth $23,265,000 after acquiring an additional 1,964,000 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.